Navigation Links
ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report

DALLAS, Texas, February 2 /PRNewswire/ -- ReportsandReports announce to have Biosimilars Series: Forecast Analysis ( Analysis/) Market Research Report in its store

The high cost and utilization of biologic drugs, coupled to the growing need to curb pharmaceutical expenditure, provides considerable momentum to the emerging biosimilars market. With a biosimilar approval pathway in place in Europe and Japan, and imminently in the US, Datamonitor expects payer pressure to drive biosimilar uptake, particularly in Germany, the US, and the UK.


    - Molecule-specific forecasts for biosimilar epoetin alpha, filgrastim,
      interferon beta, interferon alpha, human growth hormone, and

    - Molecule-specific forecasts for France, Germany, Italy, Spain, the US,
      and Japan through 2019.

    - An overview of the emerging biosimilars market, including a regulatory

    - An outline of the key issues which will impact on biosimilars uptake
      going forward.


As the first to introduce guidelines for biosimilar drug approval, Europe has emerged as the testing ground for biosimilar drugs, with biosimilars for three biologics having entered the market to date human growth hormone, epoetin alpha, and filgrastim.

The size of the US market, combined with the voracious generic erosion that characterize it, make it an attractive prospect for would-be biosimilars makers, and as such, it represents the real prize, contingent on the creation of a biosimilars approval pathway.

Although guidance for biosimilar approval was issued in Japan in 2009, this market is unlikely to experience significant biosimilar incursion through the forecast period, contributing at most 1% to total seven major market volume sales in 2019.

    Reasons to Purchase

    - Learn how biosimilar uptake for six biologic drugs is anticipated to
      change through 2019, in France, Germany, Italy, Spain, the UK, the US,
      and Japan.

    - Understand how the seven major markets compare in terms of speed and
      extent of biosimilars uptake.

    - Identify the key molecule and market specific drivers and resistors to
      biosimilar uptake.

Related Reports

HVAC in the U.S., 2nd Edition - Green and Global ( 2%80%94-green-and-global/)

Global Biomaterial Market (2009-2014) ( 9-2014/)

World Market for Biosimilars and the Potential for US Followon Biologics ( -and-the-potential-for-us-followon-bi/)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)


    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004

SOURCE MarketsandMarkets

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Globus Medical Raises $110 Million in Series E Financing Round
2. BioVascular Inc. Closes $10.87 Million Series C Financing
3. PG500 Series Presented at the AACR Annual Meeting in San Diego
4. Light Sciences Oncology Raises $40.1 Million in Series C Financing
5. Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million
6. ESBATech Raises Additional CHF 23M (USD 22M), Extending Series B Venture Financing
7. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
8. Lutonix Inc. Announces $20 Million Series B Financing
9. Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Post Your Comments:
(Date:11/25/2015)... plc (NYSE: AGN ) today announced that it has ... Attorney General,s Office to end the litigation under ... the Attorney General over the decision of Forest Laboratories, Inc., ... now generic version of memantine immediate release tablets.  Under the ... counterclaims against New York , and has ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, announced ... Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and nationally ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... “While riding ... an inventor, from Bronx, N.Y. “I thought there had to be a convenient and ... the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... cancer, I found that regular bras were incredibly uncomfortable," said an inventor from ... specialized bra." , She developed the patent-pending RECOVERY BRA for added comfort and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
Breaking Medicine News(10 mins):